Targeting the MAGE-A3 Protein in Lung Cancer

August 6, 2013
Silvia Novello, MD, PhD

Silvia Novello, MD, PhD, from the University of Turin, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.

Tweet

Silvia Novello, MD, PhD, Assistant Professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.

Though lung cancer is not as immunogenic as some other cancers, Novello says, immunotherapy is still growing in the field. With regards to the amount of disease present, early stage disease is the best situation to use a vaccine.

Clinical Pearls

A vaccine targeting the MAGE-A3 protein is in development for early disease. The trial has completed accrual and is ongoing, with about 35-55% of patients being MAGE-A3-positive. Novello believes the trial results will be clear and positive.

  • Lung cancer is not as immunogenic as some other cancers
  • Early stage disease is the best situation to use vaccines
  • A vaccine targeting the MAGE-A3 protein is in development